| INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity |
I rate INmune Bio, Inc. a speculative Strong Buy for high-risk investors, hinging on XPro's upcoming Phase II results in early Alzheimer's disease. XPro's unique mechanism targets neuroinflammation without ARIA risk, potentially serving 70% of early AD patients and outperforming current therapies. INMB's short cash runway makes positive XPro data critical for future funding, partnerships, or acquisition; failure could force shareholder dilution. |
seekingalpha.com |
2025-05-15 21:28:04 |
Czytaj oryginał (ang.) |
| INmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript |
INmune Bio, Inc. (NASDAQ:INMB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer Dr. Mark Lowdell - Chief Scientific Officer Dr. CJ Barnum - Head, Neuroscience Conference Call Participants Denis Reznik - Raymond James George Farmer - Scotiabank Tom Shrader - BTIG Laura Suriel - Alliance Global Partners Operator Greetings. And welcome to the INmune Bio First Quarter 2025 Earnings Call. |
seekingalpha.com |
2025-05-10 07:57:24 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update |
BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the quarter ended March 31, 2025 and provides a business update. |
globenewswire.com |
2025-05-08 20:10:00 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th |
Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday, May 8th, 2025 at 4:30pm EDT to discuss results for its quarter ended March 31, 2025 and to provide a corporate update. |
globenewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness |
Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry. It was established by and works in partnership with Innovate UK. |
globenewswire.com |
2025-04-14 12:00:00 |
Czytaj oryginał (ang.) |
| INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript |
INmune Bio, Inc. (NASDAQ:INMB ) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Mark Lowdell - Chief Scientific Officer Christopher Barnum - Head of Neuroscience Conference Call Participants George Farmer - Scotiabank Thomas Shrader - BTIG Denis Reznik - Raymond James Elemer Piros - Rodman James Molloy - Alliance Global Partners Operator Greetings, and welcome to the INmune Bio's. 2024 Fourth Quarter and Full Year Earnings Call. |
seekingalpha.com |
2025-03-27 22:15:17 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update |
BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update. |
globenewswire.com |
2025-03-27 18:05:00 |
Czytaj oryginał (ang.) |
| Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + |
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh ideas and fostering discussion among investors. Mitsui & Co. is given a 'buy' recommendation, driven by Warren Buffett's increased stake, stable commodity prices, and promising long-term growth from a new Australian iron ore deal. Sandisk Corporation is also seen as a 'buy' post-separation from Western Digital, with strong market performance and potential for unlocking shareholder value as an independent flash storage company. |
seekingalpha.com |
2025-03-21 15:15:01 |
Czytaj oryginał (ang.) |
| INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results |
INmune Bio's CORDstrom for RDEB shows promising results, supported by FDA designations, and could lead to a 9.8x stock revaluation. XPro for Alzheimer's has significant potential, with a $24.76 billion valuation if successful, offering a 135x stock upside. CORDstrom may act as a fail-safe for INmune Bio's stock if XPro fails, ensuring a high likelihood of substantial returns. |
seekingalpha.com |
2025-03-18 18:31:01 |
Czytaj oryginał (ang.) |
| INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer |
BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort. |
globenewswire.com |
2025-02-12 09:00:00 |
Czytaj oryginał (ang.) |
| INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) |
Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today, following a Type C meeting with the U.S. Food and Drug Administration (FDA), its intent to submit a BLA in the US and Marketing Authorization Application (MAA) in the UK and EU supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients. |
globenewswire.com |
2025-02-10 09:00:00 |
Czytaj oryginał (ang.) |
| INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 |
INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial for XPro in Alzheimer's is fully enrolled, with topline data expected around May-June 2025, marking a pivotal moment. XPro's selective TNF inhibition has shown significant reductions in key biomarkers like ptau-217 and neurofilament light, indicating strong efficacy in neurodegenerative diseases. |
seekingalpha.com |
2025-01-02 10:52:48 |
Czytaj oryginał (ang.) |
| INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers |
INmune Bio, Inc.'s decline in 2024 is attributed to broader biotech sector issues, lack of significant clinical data, and inherent risks in Alzheimer's research. XPro, INMB's lead candidate, shows potential in early-stage trials for Alzheimer's, with crucial phase 2 data expected in Q2 2025. Financially, INMB has limited runway, with cash sufficient to fund operations only into Q3 2025, necessitating successful trial outcomes for further funding. |
seekingalpha.com |
2024-12-30 17:20:48 |
Czytaj oryginał (ang.) |
| OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower |
Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- OmniScience and INmune Bio (NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune Bio's global Phase 2 Alzheimer's disease (AD) clinical trial (the “AD02 trial”) using OmniScience's flagship product, Vivo, an industry-first, genAI-powered control tower designed specifically for centralizing and analyzing vast clinical data in real time. |
globenewswire.com |
2024-12-04 11:00:00 |
Czytaj oryginał (ang.) |
| INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript |
INmune Bio, Inc. (NASDAQ:INMB ) Q3 2024 Earnings Conference Call October 31, 2024 4:00 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Gary Nachman - Raymond James George Farmer - Scotiabank Joel Beatty - Baird Thomas Shrader - BTIG Operator Greetings, and welcome to the INmune Bio Third Quarter 2024 Earnings Call. As a reminder, this conference is being recorded. |
seekingalpha.com |
2024-10-31 22:09:09 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update |
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. |
globenewswire.com |
2024-10-31 18:05:00 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB |
“Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials” Webinar to be Held on November 7, 2024, at 1 PM ET. |
globenewswire.com |
2024-10-28 10:00:00 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination |
Data from Animal Model Study Demonstrate XPro™ converts m icroglia from a demyelinating cell to a remyelinating cell |
globenewswire.com |
2024-10-24 19:03:00 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 |
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday October 31, 2024, at 4:30pm EDT to discuss results for its quarter ended September 30, 2024 and to provide a corporate update. |
globenewswire.com |
2024-10-24 13:30:00 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit |
Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that management will participate in the upcoming Maxim Healthcare Virtual Summit, to be held October 15-17, 2024. |
globenewswire.com |
2024-10-11 12:30:00 |
Czytaj oryginał (ang.) |
| INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal |
INmune Bio's initial results from cohort 1 of the phase I/II CaRe PC trial, using INKmune for the treatment of patients with mCRPC released; Additional results from higher cohorts expected throughout 2025. It is said that the global metastatic castrate resistant prostate cancer market is projected to reach $20.70 billion by 2031. INMB completed enrollment of AD02 Phase 2 study, using XPro for patients with Alzheimer's Disease expected in Q3 of 2024, with clinical data expected 6 months after last patient recruited. |
seekingalpha.com |
2024-09-30 09:04:40 |
Czytaj oryginał (ang.) |
| INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort |
BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic Castration-Resistant Prostate Cancer (mCRPC). The Company is pleased to announce initial results from the first patient cohort in the trial. |
globenewswire.com |
2024-09-26 12:00:00 |
Czytaj oryginał (ang.) |
| INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints |
BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease (AD) trial demonstrated exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the accepted endpoint for AD trials. |
globenewswire.com |
2024-09-17 12:30:00 |
Czytaj oryginał (ang.) |
| INmune Bio Announces $13.0 Million Registered Direct Offering |
Boca Raton, Florida, Sept. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) (the “Company” or “INmune Bio”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced it has entered into securities purchase agreements with new and existing institutional investors and certain directors and officers and employees of the Company (the directors and officers and employees herein referred to as the “Insiders”), for the purchase and sale of 2,341,260 shares of its common stock and warrants to purchase up to an aggregate of 2,341,260 shares of common stock at a combined purchase price per share and accompanying warrant of $5.50 for the institutional investors, and $6.50 per share and accompanying warrant for the Insiders, pursuant to a registered direct offering. The warrants will be exercisable commencing six months from the date of issuance at a price of $6.40 per share and will expire five years from the initial exercise date. The warrant term may be subject to acceleration following the satisfaction of certain conditions. In the case of Insiders that participated in the offering, if the warrant termination date is on a blackout date, then the Insiders will have an additional 60 days from the termination of the blackout date to exercise the warrant. |
globenewswire.com |
2024-09-13 12:30:00 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference |
Boca Raton, Florida, Sept. 03, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that management will participate in the following investor conferences in September and October, 2024. |
globenewswire.com |
2024-09-03 13:00:00 |
Czytaj oryginał (ang.) |
| INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript |
INmune Bio, Inc. (NASDAQ:INMB ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG George Farmer - Scotiabank Operator Greetings, and welcome to the INmune Bio Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-08-02 03:50:23 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update |
Company to Host Conference Call Today, August 1, at 4:30pm ET BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended June 30, 2024 and provides a business update. |
globenewswire.com |
2024-08-01 20:05:00 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients |
AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease is pleased to be presenting results of a new and advanced proteomic analysis at this year's annual Alzheimer's Association International Conference (AAIC) in Philadelphia, PA. |
globenewswire.com |
2024-07-29 13:00:00 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 |
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 PM EDT to discuss results for its first quarter ended June 30, 2024 and to provide a corporate update. |
globenewswire.com |
2024-07-25 12:00:00 |
Czytaj oryginał (ang.) |
| INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer |
Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics |
globenewswire.com |
2024-07-23 12:45:00 |
Czytaj oryginał (ang.) |
| INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro |
INmune Bio is developing immunotherapies for cancer and Alzheimer's, focusing on TNF and NK cell platforms. Their lead drug candidate, XPro, is in Phase 2 trials for early Alzheimer's disease and has shown promising anecdotal results. INKmune, another key candidate, is in Phase 1/2 trials for metastatic castration-resistant prostate cancer. |
seekingalpha.com |
2024-07-08 10:12:12 |
Czytaj oryginał (ang.) |